The Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Open Access
Diren Beyoğlu, Jeffrey R. Idle

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2882 - 2882

Published: March 22, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition wherein excessive fat accumulates in the liver, leading to inflammation and potential damage. In this narrative review, we evaluate tissue microbiota, how they arise their constituent microbes, role of intestinal hepatic microbiota MASLD. The history bacteriophages (phages) occurrence part causation MASLD, conversely, "phage therapy" for antibiotic resistance, obesity, are all described. metabolism bile acids dietary tryptophan histidine defined, together with impacts individual metabolites on MASLD pathogenesis. Both periodontitis dysbiosis may cause microorganisms involved these processes discussed. Novel treatment opportunities involving exist include fecal transplantation, probiotics, prebiotics, synbiotics, supplements, intermittent fasting, phages or holins endolysins. Although FDA yet approve phage therapy clinical use, there multiple FDA-approved trials, represent new horizon future

Language: Английский

Gut microbiota in health and disease: advances and future prospects DOI Creative Commons
Yusheng Zhang, Hong Wang, Yingpeng Sang

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(12)

Published: Nov. 20, 2024

Abstract The gut microbiota plays a critical role in maintaining human health, influencing wide range of physiological processes, including immune regulation, metabolism, and neurological function. Recent studies have shown that imbalances composition can contribute to the onset progression various diseases, such as metabolic disorders (e.g., obesity diabetes) neurodegenerative conditions Alzheimer's Parkinson's). These are often accompanied by chronic inflammation dysregulated responses, which closely linked specific forms cell death, pyroptosis ferroptosis. Pathogenic bacteria trigger these death pathways through toxin release, while probiotics been found mitigate effects modulating responses. Despite insights, precise mechanisms influences diseases remain insufficiently understood. This review consolidates recent findings on impact immune‐mediated inflammation‐associated conditions. It also identifies gaps current research explores potential advanced technologies, organ‐on‐chip models microbiome–gut–organ axis, for deepening our understanding. Emerging tools, single‐bacterium omics spatial metabolomics, discussed their promise elucidating microbiota's disease development.

Language: Английский

Citations

10
Microbiota-directed intervention in living donor liver transplant recipients: protocol for a randomised double-blind placebo-controlled trial DOI Creative Commons

Saraswathy S. Nair,

Anila Kutty Narayanan,

Krishnanunni Nair

et al.

BMJ Open, Journal Year: 2025, Volume and Issue: 15(3), P. e092984 - e092984

Published: March 1, 2025

Introduction Acute-on-chronic liver failure (ACLF) patients have the highest propensity for post-liver transplantation (LT) infections and mortality. Liver-associated diseases been one of primary targets synbiotic therapy to augment immunity mitigate infections. However, despite multiple studies showing benefits synbiotics in diseases, data on their use following LT are sparse. Methods analysis This randomised placebo-controlled study aims assess impact ACLF undergoing living donor (LDLT). Following randomisation by computer-generated block number sequence, 3 days prior LDLT, intervention arm will receive standard medical treatment (VSL#3 a probiotic, Yogut, prebiotic probiotic combination) 6 weeks, while control with placebo. The be followed up months clinical biochemical outcomes. objective is compare difference occurrence infectious complications between who versus placebo during 6-month period LDLT. secondary objectives include assessing qualitative quantitative change microbiota adverse reactions due synbiotics, post-LT morbidity minimum sample size comes 71 each group. first 50 protocol undergo gut microbiome using 16s metagenomic nanopore sequencing analyse microbial composition before starting synbiotics/placebo at weeks after Ethics dissemination approved Research Committee Amrita Institute Medical Sciences, Kochi, India (IEC-AIMS-2022-GISUR-203) registered Clinical Trial Registry (CTRI) CTRI/2022/10/046327. results trial disseminated presentation national/international conferences publication peer-reviewed journals. registration CTRI/2022/10/046327 –

Language: Английский

Citations

0
The Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Open Access
Diren Beyoğlu, Jeffrey R. Idle

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2882 - 2882

Published: March 22, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition wherein excessive fat accumulates in the liver, leading to inflammation and potential damage. In this narrative review, we evaluate tissue microbiota, how they arise their constituent microbes, role of intestinal hepatic microbiota MASLD. The history bacteriophages (phages) occurrence part causation MASLD, conversely, "phage therapy" for antibiotic resistance, obesity, are all described. metabolism bile acids dietary tryptophan histidine defined, together with impacts individual metabolites on MASLD pathogenesis. Both periodontitis dysbiosis may cause microorganisms involved these processes discussed. Novel treatment opportunities involving exist include fecal transplantation, probiotics, prebiotics, synbiotics, supplements, intermittent fasting, phages or holins endolysins. Although FDA yet approve phage therapy clinical use, there multiple FDA-approved trials, represent new horizon future

Language: Английский

Citations

0